In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Immucor builds blood transfusion portfolio

This article was originally published in The Gray Sheet

Executive Summary

Immucor gains BioArray Solutions' BeadChip DNA analysis system for antigen determination for donors and recipients of blood transfusions under a $117 million acquisition deal announced March 11. The cash deal also gives Immucor a 19% equity interest in a new spin-off entity that will commercialize BioArray technology outside the fields of blood transfusion and transplantation. Immucor makes automated instruments and reagents that detect and identify the properties of cell and serum components of blood prior to transfusions

You may also be interested in...

Immucor Accepts $2 Billion Private Equity Buyout, But Open To Richer Offer

Blood transfusion testing product maker Immucor will gain added financial resources for future growth following investment firm TPG Capital’s purchase of the company for $1.97 billion, the firm announced July 5.

FDA Slacking In NDI Notification Enforcement; COVID-19 'Is Not An Excuse’ – NPA

In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.

Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far

Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts